3,183
edits
Changes
Jump to navigation
Jump to search
* May 2023 - The completion of study for long time effect of the brain stimulation<ref name="RNS® System Epilepsy PAS"/>
* November 14, 2013 - FDA Premarket Approval for the NeuroPace® RNS® System<ref name="FDA Grants Premarket Approval">U.S. Food and Drug Administration. FDA Grants Premarket Approval (PMA) for the NeuroPace® RNS® System to treat Medically Refractory Epilepsy. NeuroPace, Inc. [online]. 2013, Nov. Available online at: http://www.neuropace.com/wp-content/uploads/2015/11/NeuroPace_Press_Release_PMA_Approval_2013-11-14.pdf(Retrieved 6.11.2016</ref>
a correction
=== Company & People ===
* Frank M. Fischer (- the CEO of NeuroPace)* Rebecca L. Kuhn (- Chief Financial Officer, Vice President, Finance & Administration, NeuroPace)* Martha J. Morrell, MD (- Chief Medical Officer of NeuroPace)* Isabella R. Abati (- Vice President, Regulatory Affairs, NeuroPace)* Debra L. Smolley (- Vice President, Quality Assurance & Manufacturing Operations, NeuroPace)<ref name="neuropacecompany"/>
== Important Dates ==
* January 19, 2004 - the first patient of the Feasibility Study<ref name="SSFD"/>
* December 29, 2005 - start of the Pivotal Study<ref name="SSFD"/>
* April 6, 2007 - start of the Long-term Treatment Study (LTT)<ref name="SSFD"/>
* November 14, 2013 - FDA Premarket Approval for the NeuroPace® RNS® System<ref name="FDA Grants Premarket Approval">U.S. Food and Drug Administration. FDA Grants Premarket Approval (PMA) for the NeuroPace® RNS® System to treat Medically Refractory Epilepsy. NeuroPace, Inc. [online]. 2013, Nov. Available online at: http://www.neuropace.com/wp-content/uploads/2015/11/NeuroPace_Press_Release_PMA_Approval_2013-11-14.pdf(Retrieved 6.11.2016</ref>
* May 2023 - The completion of study for long time effect of the brain stimulation<ref name="RNS® System Epilepsy PAS"/>
== Enhancement/Therapy/Treatment ==
